Special Issue

Hiding in Plain Sight – Vaccines against Highly Variable Pathogens

Message from the Guest Editors

Vaccination has driven tremendous gains in public health. Vaccines against highly variable pathogens have proved difficult to obtain. Many pathogens display incredible capacity to change their antigenic. In order to unlock pathways to vastly improved vaccines, including but not limited to:

- A mechanistic understanding of how the immune system hierarchically recognizes and responds to antigens (i.e., immunogenicity and immunodominance);
- Strategies to rationally design and/or engineer vaccine immunogens to maximize the conservation or display of highly conserved, protective epitopes (i.e., immunefocusing);
- Strategies to selectively promote and/or maintain highly cross-reactive B- and T-cell responses for broad and durable protection.

This Special Issue will cover the most recent advances and outstanding challenges surrounding immunity and vaccine development against variable viruses, parasites, and bacteria. This Issue aims to incorporate diverse perspectives from specialists in immunology; vaccinology; bio-engineering; structural biology; bacterial, viral, or parasite immunology; and more.

Guest Editors

Dr. Davide Angeletti

Institutionen för biomedicin, Göteborgs universitet, Gothenburg, Sweden

Dr. Adam Wheatley

Department of Microbiology and Immunology, University of Melbourne, Melbourne, Australia

Deadline for manuscript submissions

closed (31 December 2020)



an Open Access Journal by MDPI

Impact Factor 5.2 CiteScore 8.9 Indexed in PubMed



mdpi.com/si/41540

Vaccines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/ vaccines





an Open Access Journal by MDPI

Impact Factor 5.2 CiteScore 8.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2024).

